230 related articles for article (PubMed ID: 32167078)
1. Exonuclease 1 (Exo1) Participates in Mammalian Non-Homologous End Joining and Contributes to Drug Resistance in Ovarian Cancer.
He D; Li T; Sheng M; Yang B
Med Sci Monit; 2020 Mar; 26():e918751. PubMed ID: 32167078
[TBL] [Abstract][Full Text] [Related]
2. DNA end resection is needed for the repair of complex lesions in G1-phase human cells.
Averbeck NB; Ringel O; Herrlitz M; Jakob B; Durante M; Taucher-Scholz G
Cell Cycle; 2014; 13(16):2509-16. PubMed ID: 25486192
[TBL] [Abstract][Full Text] [Related]
3. FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer.
Zhou J; Wang Y; Wang Y; Yin X; He Y; Chen L; Wang W; Liu T; Di W
PLoS One; 2014; 9(5):e96989. PubMed ID: 24824601
[TBL] [Abstract][Full Text] [Related]
4. DNA-damage-induced degradation of EXO1 exonuclease limits DNA end resection to ensure accurate DNA repair.
Tomimatsu N; Mukherjee B; Harris JL; Boffo FL; Hardebeck MC; Potts PR; Khanna KK; Burma S
J Biol Chem; 2017 Jun; 292(26):10779-10790. PubMed ID: 28515316
[TBL] [Abstract][Full Text] [Related]
5. Mammalian Exo1 encodes both structural and catalytic functions that play distinct roles in essential biological processes.
Schaetzlein S; Chahwan R; Avdievich E; Roa S; Wei K; Eoff RL; Sellers RS; Clark AB; Kunkel TA; Scharff MD; Edelmann W
Proc Natl Acad Sci U S A; 2013 Jul; 110(27):E2470-9. PubMed ID: 23754438
[TBL] [Abstract][Full Text] [Related]
6. CircUGGT2 facilitates progression and cisplatin resistance of bladder cancer through nonhomologous end-joining pathway.
Lyu F; Huang S; Yan Z; He Q; Liu C; Cheng L; Cong Y; Chen K; Song Y; Xing Y
Cell Signal; 2024 Jul; 119():111164. PubMed ID: 38583745
[TBL] [Abstract][Full Text] [Related]
7. Human Ku70/80 protein blocks exonuclease 1-mediated DNA resection in the presence of human Mre11 or Mre11/Rad50 protein complex.
Sun J; Lee KJ; Davis AJ; Chen DJ
J Biol Chem; 2012 Feb; 287(7):4936-45. PubMed ID: 22179609
[TBL] [Abstract][Full Text] [Related]
8. CtIP contributes to non-homologous end joining formation through interacting with ligase IV and promotion of TMZ resistance in glioma cells.
Yang B; Han N; Sun J; Jiang H; Xu HY
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2092-2102. PubMed ID: 30915754
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of exonuclease 1 caused by homology-dependent repair confers cisplatin resistance to gastric cancer cells.
Mao P; Wu S; Fan Y
Can J Physiol Pharmacol; 2022 Sep; 100(9):903-914. PubMed ID: 35767882
[TBL] [Abstract][Full Text] [Related]
10. Dysfunctional activity of classical DNA end-joining renders acquired resistance to carboplatin in human ovarian cancer cells.
Yoon MJ; Cha H; Ahn J; Lee D; Jeong HS; Koo HS; Kang YJ
Cancer Lett; 2021 Nov; 520():267-280. PubMed ID: 34375710
[TBL] [Abstract][Full Text] [Related]
11. EXO1 suppresses double-strand break induced homologous recombination between diverged sequences in mammalian cells.
Chen CC; Avdievich E; Zhang Y; Zhang Y; Wei K; Lee K; Edelmann W; Jasin M; LaRocque JR
DNA Repair (Amst); 2017 Sep; 57():98-106. PubMed ID: 28711786
[TBL] [Abstract][Full Text] [Related]
12. Exonuclease 1 is a critical mediator of survival during DNA double strand break repair in nonquiescent hematopoietic stem and progenitor cells.
Desai A; Qing Y; Gerson SL
Stem Cells; 2014 Feb; 32(2):582-93. PubMed ID: 24420907
[TBL] [Abstract][Full Text] [Related]
13. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
Yang S; Wang XQ
BMC Cancer; 2017 May; 17(1):344. PubMed ID: 28526069
[TBL] [Abstract][Full Text] [Related]
14. PAXX Is an Accessory c-NHEJ Factor that Associates with Ku70 and Has Overlapping Functions with XLF.
Tadi SK; Tellier-Lebègue C; Nemoz C; Drevet P; Audebert S; Roy S; Meek K; Charbonnier JB; Modesti M
Cell Rep; 2016 Oct; 17(2):541-555. PubMed ID: 27705800
[TBL] [Abstract][Full Text] [Related]
15. ELL2 regulates DNA non-homologous end joining (NHEJ) repair in prostate cancer cells.
Zang Y; Pascal LE; Zhou Y; Qiu X; Wei L; Ai J; Nelson JB; Zhong M; Xue B; Wang S; Yang D; Lan L; Shan Y; Wang Z
Cancer Lett; 2018 Feb; 415():198-207. PubMed ID: 29179998
[TBL] [Abstract][Full Text] [Related]
16. Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.
McCormick A; Donoghue P; Dixon M; O'Sullivan R; O'Donnell RL; Murray J; Kaufmann A; Curtin NJ; Edmondson RJ
Clin Cancer Res; 2017 Apr; 23(8):2050-2060. PubMed ID: 27702817
[No Abstract] [Full Text] [Related]
17. Discovery of UMI-77 as a novel Ku70/80 inhibitor sensitizing cancer cells to DNA damaging agents in vitro and in vivo.
Chen X; Chen C; Luo C; Liu J; Lin Z
Eur J Pharmacol; 2024 Jul; 975():176647. PubMed ID: 38754534
[TBL] [Abstract][Full Text] [Related]
18. A novel small molecule inhibitor of the DNA repair protein Ku70/80.
Weterings E; Gallegos AC; Dominick LN; Cooke LS; Bartels TN; Vagner J; Matsunaga TO; Mahadevan D
DNA Repair (Amst); 2016 Jul; 43():98-106. PubMed ID: 27130816
[TBL] [Abstract][Full Text] [Related]
19. KU70 Inhibition Impairs Both Non-Homologous End Joining and Homologous Recombination DNA Damage Repair Through SHP-1 Induced Dephosphorylation of SIRT1 in T-Cell Acute Lymphoblastic Leukemia (T-ALL) [corrected].
Yu W; Li L; Wang G; Zhang W; Xu J; Liang A
Cell Physiol Biochem; 2018; 49(6):2111-2123. PubMed ID: 30273928
[TBL] [Abstract][Full Text] [Related]
20. Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.
Lombardi AJ; Hoskins EE; Foglesong GD; Wikenheiser-Brokamp KA; Wiesmüller L; Hanenberg H; Andreassen PR; Jacobs AJ; Olson SB; Keeble WW; Hays LE; Wells SI
Clin Cancer Res; 2015 Apr; 21(8):1962-72. PubMed ID: 25609062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
